

Stock Data

Share Price:	1.95p
Market Cap:	£20.9m
Shares in issue:	1,072.4m

Company Profile

Sector:	Healthcare
Ticker:	SKIN
Exchange:	AIM

Activities

Integumen plc ('SKIN', 'the Group') is a vertically integrated test services company focused on developing and commercialising technology and products that scientifically prove the impact of skin care product claims for healthcare, life sciences, clinical research, pharmaceutical and cosmetics industries.

1-year Share price performance



Source: [LSE](#)

Past performance is not an indication of future performance.

Turner Pope contact details

Turner Pope Investments ('TPI') Limited
8 Frederick's Place
London EC2R 8AB

Tel: 0203 657 0050
Email: info@turnerpope.com
Web: www.turnerpope.com

Attention is drawn to the disclaimers and risk warnings at the end of this document.

This is a non-independent marketing communication. The analyst who has prepared this report is aware that TPI has a relationship with the company covered in this report. Accordingly, it has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

TPI acts as sole broker to Integumen plc.

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Barry Gibb

Research Analyst

Tel: 0203 657 0050
barry.gibb@turnerpope.com

Andrew Thacker

Corporate Broking & Sales

Tel: 0203 657 0050
andy.thacker@turnerpope.com

Integumen plc

Integumen this morning announced the launch of another world first, this time in the form of a remote clinical skin trials platform. It is designed to provide both convenience and safety for trial volunteers, ranging from healthy through to immune-suppressed, aged or infirm candidates, that otherwise remain disrupted by the Pandemic lockdown. By harvesting the microbiome of a human volunteer skin and transporting it to Group subsidiary, [Labskin](#), for transplantation onto laboratory-grown skin, a clinical-grade medium containing an exact replica of the individual's unique microflora can be created. The service is presently also being further adapted in order for individual consumers to undertake trial cosmetic skin diagnostics, thereby opening a new international market opportunity with a giant global industry that wishes to add value through bespoke/personalised products.

Relevance of the human skin biome

Working with the Group's Rinocloud software/AI division, Labskin has created this platform as an extension to the Labskin AI virtual disease modelling development program that has already transformed the Integumen business model over the last 24 months. The platform is anchored in Labskin technology's ability to harvest and replicate a human subject's microbiome.

Skin microbiota is the term used to describe the multitudes of different bacteria, viruses and fungi that live on the surface of human skin; the microbiome is the genetic material of these microbes to which all skin disease/reactive conditions are believed to be intrinsically linked. The background to this is the theory that concludes emotions (depression, stress, anxiety etc.), along with changes to an individual's metabolic condition, alters the gut microbiome which is then transferred to the skin, resulting in flare-up of psoriasis, acne, eczema, dermatitis etc. and represents a global problem that as [many as 1-in-4 individuals suffer](#) during their lifetime. Given the number of variables involved, however, clinical testing of potential new therapies is beset with problems and alternative testing solutions are urgently required, particularly following moves by the [US](#), [EU](#) and [China](#) to accelerate the ending of the use of animals in such skin product testing.

In response, Labskin has developed a commercial, full-thickness human skin equivalent that differentiates itself from competition by uniquely being able to be colonised with individual sample microflora. As such, developers of skin-related drugs and cosmetics can utilise it in a clinical setting to create a repository of data and predictive analysis in support of commercialisation of new medical and personal products. Given that the global skincare and cosmetics market is estimated to have an [annual value of some US\\$450 billion](#), the opportunity presented to Integumen not only to promote 'whole-body' health but also to sustain the condition of the human body's largest organ is potentially substantial.

Recognising the needs of a post-Pandemic environment

Given the response that is widely expected from international governments in a post-Pandemic environment, Integumen's unique skills and capabilities are likely to remain in demand going forward. Its management's ability to pre-empt such needs moreover, along with those of the companies and organisations that it has established commercial agreements/partnerships with, suggests it should enjoy strong, ongoing, contracted growth for some years to come. With the weight of anticipated demand from global-scale manufacturers seen likely to test the Group's expanded laboratory capacity before the end of current period, TPI's Initiation research on Integumen plc set a target price of 3.23p/share*.

Please note our valuation is relative and such valuation may never be realised, therefore please do not base investment decisions on this valuation alone. *£=1.20US\$

THIS DOCUMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION INTO THE UNITED STATES OF AMERICA, JAPAN, CANADA OR AUSTRALIA.

Conflicts

This is a non-independent marketing communication under the rules of the Financial Conduct Authority ("FCA"). The analyst who has prepared this report is aware that Turner Pope Investments (TPI) Limited ("TPI") has a relationship with the company covered in this report. Accordingly, the report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing by TPI or its clients ahead of the dissemination of investment research.

TPI manages its conflicts in accordance with its conflict management policy. For example, TPI may provide services (including corporate finance advice) where the flow of information is restricted by a Chinese wall. Accordingly, information may be available to TPI that is not reflected in this document. TPI may have acted upon or used research recommendations before they have been published.

Risk Warnings

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Any opinions expressed in this document are those of TPI's research analyst. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price.

The value of securities, particularly those of smaller companies, can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of smaller company securities may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results.

AIM is a market designed primarily for emerging or smaller companies and the rules of this market are less demanding than those of the Official List of the UK Listing Authority; consequently, AIM investments may not be suitable for some investors. Liquidity may be lower and hence some investments may be harder to realise.

Specific disclaimers

TPI acts as sole broker to Integumen plc ("Integumen") which is listed on the AIM Market of the London Stock Exchange ("AIM"). TPI's private and institutional clients may hold, subscribe for or buy or sell Integumen's securities.

Opinions and estimates in this document are entirely those of TPI as part of its internal research activity. TPI has no authority whatsoever to make any representation or warranty on behalf of Integumen.

General disclaimers

This document, which presents the views of TPI's research analyst, cannot be regarded as "investment research" in accordance with the FCA definition. The contents are based upon sources of information believed to be reliable but no warranty or representation, express or implied, is given as to their accuracy or completeness. Any opinion reflects TPI's judgement at the date of publication and neither TPI nor any of its directors or employees accepts any responsibility in respect of the information or recommendations contained herein which, moreover, are subject to change without notice. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price. TPI does not undertake to provide updates to any opinions or views expressed in this document. TPI accepts no liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by applicable law).

The information in this document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

This document is approved and issued by TPI for publication only to UK persons who are authorised persons under the Financial Services and Markets Act 2000 and to professional clients, as defined by Directive 2004/39/EC as set out in the rules of the Financial Conduct Authority. This document may not be published, distributed or transmitted to persons in the United States of America, Japan, Canada or Australia. This document may not be copied or reproduced or re-distributed to any other person or organisation, in whole or in part, without TPI's prior written consent.

Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.